The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma

For approximately three decades, autologous hematopoietic cell transplantation (auto-HCT) has been the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after frontline therapy. This approach is limited due to the intensity of chemotherapy and the pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Albanyan, Omar, Chavez, Julio, Munoz, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Recent Advances in Immunotherapy for Lymphoma and Multiple Myeloma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730015/
https://www.ncbi.nlm.nih.gov/pubmed/36505886
http://dx.doi.org/10.1177/20406207221141511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730015/
https://www.ncbi.nlm.nih.gov/pubmed/36505886
http://dx.doi.org/10.1177/20406207221141511

Ejemplares similares